Rituximab for the first-line treatment of stage III-IV follicular lymphoma

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma. NICE technology appraisal guidance 226 (2011).

Rituximab for the treatment of relapsed or refractory stage III of IV follicular non-Hodgkin's lymphoma (review of NICE technology appraisal guidance 37). NICE technology appraisal guidance 137 (2008).

Improving outcomes in haematological cancers – the manual. NICE cancer service guidance (2003).